StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)

Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –

Vertex Pharmaceuticals Non-GAAP provision for income taxes by Quarter

Non-GAAP provision for income taxes ($M) ($M)

Vertex Pharmaceuticals Non-GAAP provision for income taxes: $324M in Q2 2026, up 14.7% from a year earlier. That is the highest of the 36 quarters on record here.

Latest, Q2 2026
324
Period ended Jun 30, 2026
Change on a year earlier
+14.7%
282 in Q2 2025
History
36 quarters
Since Q1 2017
Sources
32
Documents cited below

Where the Q2 2026 figure comes from

“|| Non-GAAP provision for income taxes | $ | 323.7 | $ | 282.2 | $ | 603.8 | $ | 526.4”

Source: Form 8-K (ex-991_q22026.htm, filed 2026-08-03) ↗

Reported in Form 8-K EX-99.1 Earnings Releases (GAAP to Non-GAAP Reconciliations).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNon-GAAP provision for income taxes ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026324+14.7%Form 8-K (ex-991_q22026.htm, filed 2026-08-03) ↗
Q1 2026Mar 31, 2026280+14.7%Form 8-K (ex-991_q12026.htm, filed 2026-05-04) ↗
Q4 2025Dec 31, 2025201-28.2%Form 8-K (ex-991_q42025.htm, filed 2026-02-12) ↗
Q3 2025Sep 30, 2025264-6.7%Form 8-K (ex-991_q32025.htm, filed 2025-11-03) ↗
Q2 2025Jun 30, 2025282-6.1%Form 8-K (ex-991_q22026.htm, filed 2026-08-03) ↗
Q1 2025Mar 31, 2025244-6.5%Form 8-K (ex-991_q12026.htm, filed 2026-05-04) ↗
Q4 2024Dec 31, 2024280+30.5%Form 8-K (ex-991_q42025.htm, filed 2026-02-12) ↗
Q3 2024Sep 30, 2024283+10.1%Form 8-K (ex-991_q32025.htm, filed 2025-11-03) ↗
Q2 2024Jun 30, 2024301+11.6%Form 8-K (ex-991_q22025.htm, filed 2025-08-04) ↗
Q1 2024Mar 31, 2024261+21.8%Form 8-K (ex-991_q12025.htm, filed 2025-05-05) ↗
Q4 2023Dec 31, 2023214-3.3%Form 8-K (ex-991_q42024.htm, filed 2025-02-10) ↗
Q3 2023Sep 30, 2023257-9.3%Form 8-K (ex-991_q32024.htm, filed 2024-11-04) ↗
Q2 2023Jun 30, 2023269+4.2%Form 8-K (ex-991_q22024.htm, filed 2024-08-01) ↗
Q1 2023Mar 31, 2023214-13.9%Form 8-K (ex-991_q12024.htm, filed 2024-05-06) ↗
Q4 2022Dec 31, 2022222+9.9%Form 8-K (ex-991_q42023.htm, filed 2024-02-05) ↗
Q3 2022Sep 30, 2022283+22.1%Form 8-K (ex-991_q32023.htm, filed 2023-11-06) ↗

Breakdown

What makes up non-GAAP provision for income taxes

Cite this data

StockData. (2026). Vertex Pharmaceuticals Non-GAAP provision for income taxes ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/nongaap-tax

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.